Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.76
+0.01 (0.02%)
At close: Apr 28, 2026, 4:00 PM EDT
52.71
-0.05 (-0.09%)
After-hours: Apr 28, 2026, 6:37 PM EDT
Soleno Therapeutics Revenue
In the year 2025, Soleno Therapeutics had annual revenue of $190.41M. Soleno Therapeutics had revenue of $91.73M in the quarter ending December 31, 2025.
Revenue (ttm)
$190.41M
Revenue Growth
n/a
P/S Ratio
14.33
Revenue / Employee
$1,046,181
Employees
182
Market Cap
2.73B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 510.17M |
| Tarsus Pharmaceuticals | 451.36M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Immunome | 6.94M |
| Celldex Therapeutics | 1.55M |
SLNO News
- 13 days ago - Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers - GlobeNewsWire
- 13 days ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 19 days ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 21 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 22 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 22 days ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 22 days ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire
- 27 days ago - Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman - PRNewsWire